Cibus (CBUS) 17th Annual LD Micro Main Event Conference summary
Event summary combining transcript, slides, and related documents.
17th Annual LD Micro Main Event Conference summary
3 Feb, 2026Technology and innovation
Focus on gene editing to develop crop traits that are indistinguishable from natural or traditional breeding, enabling rapid introduction of new characteristics in major crops.
Rapid Trait Development System (RTDS) accelerates trait development from centuries to weeks or months, using precise DNA edits without introducing foreign DNA.
Traits target productivity, weed control, disease resistance, and yield protection, with ongoing development for canola, rice, and soybean.
Technology enables stacking and updating of traits, similar to software updates, with low incremental costs per new variety.
Regulatory changes globally, including in Europe, now differentiate gene-edited crops from GMOs, opening new markets and facilitating trade.
Business model and partnerships
Operates a trait licensing and royalty business, partnering with major seed companies and non-seed partners for sustainable ingredients.
Five-trait pipeline focused on canola, rice, and soybean, with traits for weed management, disease resistance, and pod shatter reduction.
No exclusive licensing; traits are licensed to multiple customers, with field trials demonstrating effectiveness before customer adoption.
Royalty revenue is expected to begin in 2026, with a stable and growing addressable market, especially in soybeans.
Estimated trait value per acre ranges from $5 to $15, with rice traits offering higher annual royalty potential.
Financial outlook and funding
Currently pre-revenue, with reported income from R&D funding rather than trait royalties.
Annual cash burn is under $50 million, with financing needs until royalty revenue starts in 2026.
Plans to bridge funding gap through equity raises and potentially royalty debt.
Cost to upgrade or add new traits is significantly lower than traditional GMO development, often less than $100,000 per variety.
Long-term royalty streams are expected to be highly recurring and sticky, similar to historical GMO trait royalties.
Latest events from Cibus
- Advanced Rice and ingredient programs, cut costs, and raised funds for 2026 milestones.CBUS
Q4 202517 Mar 2026 - Q2 2024 saw commercial expansion, advanced trait milestones, and a $28.5M net loss.CBUS
Q2 20242 Feb 2026 - Gene editing is transforming agriculture, driving efficiency, sustainability, and high-margin growth.CBUS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Gene editing traits for major crops are poised for rapid global adoption and strong royalty growth.CBUS
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 net loss of $201.5M from goodwill impairment; cost savings and commercialization ongoing.CBUS
Q3 202415 Jan 2026 - Industrialized gene editing and royalty-driven traits set the stage for scalable agtech growth.CBUS
Sidoti Micro-Cap Virtual Conference9 Jan 2026 - Q4 2024 net loss narrowed, cash runway extended, and gene editing platforms advanced.CBUS
Q4 202424 Dec 2025 - Net loss widened to $49.4M on impairment, with cash needs beyond Q3 2025 despite revenue growth.CBUS
Q1 202527 Nov 2025 - Gene-edited crop traits set for 2027 launch, driving royalty growth and global market access.CBUS
Alliance Global Partners Healthcare Company Showcase25 Nov 2025